Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.03 USD | -8.33% | 0.00% | -95.72% |
May. 30 | First Motion for Exclusivity Period Extension Filed by DMK Pharmaceuticals Corporation | CI |
May. 08 | Motion for Asset Sale Approved for DMK Pharmaceuticals Corporation | CI |
Financials (USD)
Sales 2021 | 2.21M | Sales 2022 | 4.76M | Capitalization | 25.39M |
---|---|---|---|---|---|
Net income 2021 | -45M | Net income 2022 | -26M | EV / Sales 2021 | 31.5 x |
Net cash position 2021 | 20.53M | Net cash position 2022 | 433K | EV / Sales 2022 | 5.25 x |
P/E ratio 2021 |
-1.9
x | P/E ratio 2022 |
-0.96
x | Employees | 12 |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 90.68% |
Latest transcript on DMK Pharmaceuticals Corporation
1 day | -8.33% | ||
3 months | -53.85% | ||
6 months | -95.00% | ||
Current year | -95.72% |
Managers | Title | Age | Since |
---|---|---|---|
Ebrahim Versi
CEO | Chief Executive Officer | 71 | 23-05-24 |
Seth Cohen
DFI | Director of Finance/CFO | 42 | 23-10-15 |
Robert H. Uhl
IRC | Investor Relations Contact | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Howard Birndorf
BRD | Director/Board Member | 74 | 19-08-25 |
Ebrahim Versi
CEO | Chief Executive Officer | 71 | 23-05-24 |
Vickie Reed
BRD | Director/Board Member | 62 | 22-05-23 |
Date | Price | Change | Volume |
---|---|---|---|
24-06-07 | 0.03 | -8.33% | 3,327 |
24-06-06 | 0.0327 | +9.08% | 6,204 |
24-06-05 | 0.03 | -5.06% | 1,797 |
24-06-04 | 0.0316 | +0.06% | 2,526 |
24-06-03 | 0.0316 | +5.27% | 8,708 |
Delayed Quote OTC Markets, June 07, 2024 at 12:48 pm EDT
More quotes1st Jan change | Capi. | |
---|---|---|
-95.72% | 303K | |
+45.82% | 765B | |
-6.16% | 354B | |
+19.86% | 331B | |
+9.32% | 299B | |
+18.45% | 248B | |
-0.78% | 219B | |
+11.88% | 216B | |
+5.90% | 164B | |
-0.73% | 162B |
- Stock Market
- Equities
- DMKPQ Stock